The identification of pharmaceutically targetable biomarkers is essential for improving therapeutic options for cancer patients. In this study, the authors identify MAP3K8 as a potential predictive marker for MEK inhibitor treatment in patients with aggressive ovarian cancer.
- Tina Gruosso
- Camille Garnier
- Fatima Mechta-Grigoriou